Life Sciences
Research by C. Stock and colleagues in life sciences provides new insights
Published in Cancer Weekly, March 23rd, 2010
Data detailed in 'Temsirolimus' have been presented. "Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors," scientists writing in the journal Recent Results In Cancer Research Fortschritte Der Krebsforschung Progres Dans Les report.
"Patients with advanced renal cell carcinoma (RCC) and a poor prognosis who received a once-weekly intravenous (IV) infusion of temsirolimus 25 mg, experienced significant survival benefits when compared with patients receiving standard...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-03-23)
More Articles from Cancer Weekly
- American Cancer Society
Improvements needed in genomic test result discussions - American Cancer Society
Study finds cancer mortality has declined since initiation of 'war on cancer' - Columbia University Medical Center
Acupuncture may relieve joint pain caused by some breast cancer treatments - EQ Biosciences, Inc.
Supplement blocks the initiation of breast cell mutations by estrogens - Journal of the National Cancer Institute
High weight associated with risk of colorectal tumors without microsatellite instability - University of Leicester
MRC scientists announce advance in understanding body's natural defenses - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
